Tempest Therapeutics appoints Christine Pellizzari to board, enters new exec employment agreements

Tempest Therapeutics, Inc.

Appointed Christine Pellizzari as Class II Director, serving on Audit Committee; term expires 2023.
CEO Stephen Brady gets $475,283 base salary, 40% target bonus, 250k stock options, and severance of 12–18 months salary plus bonus.
President Thomas Dubensky gets $476,283 base, 40% target bonus, 250k options; severance of 12–18 months salary plus bonus.
CMO Samuel Whiting gets $400k base, 35% target bonus; severance of 9–12 months salary plus bonus.
All directors and executive officers entered indemnification agreements with the Company.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Christine Pellizzari

Class II Director

TPST · Tempest Therapeutics, Inc.

Effective: 2021-07-01
Filed: July 7, 2021, 7:59 PM ET

On July 1, 2021, the Board appointed Christine Pellizzari as a Class II Director.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Christine Pellizzari was appointed as Class II Director at Tempest Therapeutics, Inc..

Action: appointed
Role: Class II Director

Exact text from the filing

On July 1, 2021, the Board appointed Christine Pellizzari as a Class II Director.

View on SEC.gov

Tempest Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-21-209988

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.